More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

Appendix 4C Cash Flow Report

Oct 26, 2021 at 11:08 PM EDT · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Oct 26, 2021 at 11:08 PM EDT

On 6ix: 6ix.com/news/appendix-4c-cash-flow-report-37

Clarity Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Clarity Pharmaceuticals Ltd. on 6ix

Earlier from Clarity Pharmaceuticals

  • Recruitment closed on C-BOBCAT SAR-Bombesin trialOct 18, 2021
  • App 4E Preliminary Final Report 30 June 2021Aug 25, 2021

Later from Clarity Pharmaceuticals

  • Dosimetry Recruitment of theranostic prostate trial completeNov 9, 2021
  • Quarterly Activity ReportNov 18, 2021
  • Managing Directors Presentation to Annual General MeetingNov 24, 2021
  • SARTATE Neuroblastoma trial advances to cohort 2Jan 31, 2022
  • Clarity receives $3.26 million R&D tax incentive refundFeb 3, 2022
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer